<DOC>
	<DOCNO>NCT01274559</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , placebo-controlled study participant primary hypercholesterolemia mixed dyslipidemia , elevate low density lipoprotein-cholesterol ( LDL-C ) ass efficacy safety extend release ( ER ) niacin/laropiprant [ ERN/LRPT ( MK-0524A ) ] add follow ongoing lipid-modifying therapy ( LMT ) : simvastatin , atorvastatin , rosuvastatin monotherapy , ezetimibe/simvastatin fix dose combination ( FDC ) , statin co-administered ezetimibe . The study base hypothesis ERN/LRPT 2 g daily superior placebo lower LDL-C Week 12 treatment .</brief_summary>
	<brief_title>Efficacy Safety Extended Release ( ER ) Niacin/Laropiprant When Added Ongoing Lipid-Modifying Therapy Patients With High Cholesterol Abnormal Lipid Levels ( MK-0524A-133 )</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Niacin</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<criteria>Has history primary hypercholesterolemia mixed dyslipidemia . Must meet one risk category ( high , high moderate corresponding LDLC criterion Visit 2 . Has TG level &lt; 500 mg/dL ( &lt; 5.65 mmol/L ) . Has stable dose one follow lipidmodifying therapy ( LMTs ) least 6 week prior Visit 1 , agree remain type dose LMT duration study : Monotherapy : statin Combination Therapy : ezetimibe/simvastatin tablet Coadministration Therapy : statin coadministered ezetimibe Is male female ≥18 year age day sign informed consent . A female must meet ONE follow : Of reproductive potential agrees remain abstinent use ( partner use ) 2 acceptable method birth control study duration . Not reproductive potential eligible without require use contraception . Definition `` reproductive potential '' : one either follow : reach natural menopause , define : 6 month spontaneous amenorrhea serum FSH level ( Visit 1 ) postmenopausal range ( per central lab ) 12 month spontaneous amenorrhea.Spontaneous amenorrhea include case underlie disease cause amenorrhea ( e.g. , anorexia nervosa ) . 6 week post surgical hysterectomy , bilateral oophorectomy without hysterectomy . Bilateral tubal ligation without subsequent restorative procedure . Understands study 's procedure , alternative treatment available , risk involve study , voluntarily agree participate give write informed consent . Exclusion Criteria Has take prohibit LMT within 6 week Visit 1 . Examples prohibit LMT include bile acid sequestrants , fibrates ( monotherapy , coadministration combination LMT ) , niacin &gt; 50 mg , red yeast rice product . Has change type dose acceptable LMT regimen within 6 week Visit 1 . Is pregnant , breastfeeding , expect conceive study include 14day poststudy followup . Has history malignancy ≤5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Female expect donate egg study , include 14day followup . Is unlikely adhere study procedure , keep appointment , plan relocate study . Has participate study , include poststudy followup , investigational compound ( nonlipidmodifying ) within 30 day Visit 1 lipidmodifying compound ( investigational market ) , within 6 week Visit 1 . Has donate and/or receive blood follow : donate blood product phlebotomy &gt; 300 mL within 8 week prior sign inform consent . intend give receive blood product study . intend donate 250 mL blood product within 8 week follow last study visit . Has follow exclusionary laboratory value Visit 2 Creatinine clearance ( eGFR ) &lt; 30 mL/min ( 0.50 mL/s ) ALT ( SGPT ) &gt; 1.5 x ULN AST ( SGOT ) &gt; 1.5 x ULN CK &gt; 2 x ULN Has use recreational illicit drug within 1 year signing informed consent . Was &lt; 80 % compliant LMT placebo Visit 2 , AND opinion investigator , believe unable maintain least 80 % compliance dose active treatment period . Has chronic heart failure define New York Heart Association ( NYHA ) Classes III IV , uncontrolled cardiac arrhythmia , poorly control hypertension ( systolic blood pressure &gt; 160 mm Hg diastolic &gt; 100 mm Hg ) . Has Type 1 Type 2 diabetes mellitus meet one follow criterion : Is poorly control ( HbA1C &gt; 8.0 % Visit 1 ) Is newly diagnose ( within 3 month Visit 1 ) Has recently experience repeat hypoglycemia unstable glycemic control ( within 3 month Visit 1 ) . Is take new recently adjust antidiabetic pharmacotherapy ( exception ± ≤ 10 unit insulin ) within 3 month Visit 1 . Has uncontrolled endocrine metabolic disease know influence serum lipid lipoprotein ( i.e. , secondary cause hyperlipidemia hyper hypothyroidism . Has nephrotic syndrome clinically significant renal disease . Has active peptic ulcer disease within 3 month Visit 1 . Has history hypersensitivity allergic reaction niacin niacin contain product . Has history myocardial infarction , stroke , coronary artery bypass surgery revascularization procedure , unstable angina angioplasty within 3 month Visit 1 . Has arterial bleeding . Has history ileal bypass , gastric bypass significant condition associate malabsorption rapid weight loss within 18 month Visit 1 . Has active chronic hepatobiliary hepatic disease . Is Chinese simvastatin 80 mg product contain simvastatin 80 mg Visit 1 . Is receive treatment systemic steroid ( intravenous , injected , oral steroid ) OR systemic anabolic agent . Consumes 3 alcoholic drink give day 14 drink per week . Is take follow antioxidant vitamin day : Vitamin C excess 1500 mg Vitamin E excess 45 IU men , 36 IU woman Beta Carotene 15000 IU men , 12000 IU woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MK-0524A/ER</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Niacin</keyword>
	<keyword>Laropiprant</keyword>
</DOC>